BRIEF-Regenxbio Enters Settlement And Release Agreement With Glaxosmithkline On March 18, 2026 - SEC Filing

REGENXBIO, Inc. +3.26%
GlaxoSmithKline plc Sponsored ADR +2.14%

REGENXBIO, Inc.

RGNX

9.49

+3.26%

GlaxoSmithKline plc Sponsored ADR

GSK

58.35

+2.14%

- SEC Filing:

  • REGENXBIO INC - ENTERS SETTLEMENT AND RELEASE AGREEMENT WITH GLAXOSMITHKLINE ON MARCH 18, 2026 - SEC FILING

  • REGENXBIO INC - TO PAY $10.0 MILLION TO GLAXOSMITHKLINE FOR ALLEGED UNDERPAYMENT OF SUBLICENSE FEES - SEC FILING

  • REGENXBIO INC - SETTLEMENT AGREEMENT INCLUDES MUTUAL RELEASES OF PAST AND CERTAIN FUTURE CLAIMS - SEC FILING

  • REGENXBIO INC - TO CONTINUE TO PAY GSK AMOUNTS RECEIVED FROM SUBLICENSEES PURSUANT TO EXISTING SUBLICENSE AGREEMENTS - SEC FILING

Source text: [ID:n0001193125-26-117913]

Further company coverage: RGNX.O